Tag Archives: declining

Chemotherapy Losing (Lost?) Its Luster

Story at-a-glance

  • Research dating back over a decade suggests many women with breast cancer can opt for gentler versions of chemotherapy, or skip it altogether, without harming their chances of recovery
  • According to the American Society of Clinical Oncology (ASCO), many cancer patients are being overtreated to their detriment; an estimated 70 percent of women with early stage breast cancer probably do not need chemotherapy, and fare just as well without it
  • The Oncotype DX test can help determine whether a breast cancer patient might benefit from chemo by measuring the activity of 21 genes involved in cancer recurrence
  • According to ASCO’s findings, women with estrogen-sensitive breast cancer that test negative for HER2, and whose tumors are smaller than 5 centimeters, have not spread to the lymph nodes, and have an Oncotype DX score between 11 and 25, can forgo chemo
  • An increasing number of cancer patients are now electing not to use chemo. A recent survey found the overall use of chemo declined from 34.5 to 21.3 percent between 2013 and 2015

By Dr. Mercola

Surgery, drugs and radiation — aka the “cut, poison, burn” strategy — are typically the only solutions offered by most conventional oncologists to treat cancer, and upon receiving a cancer diagnosis most people are willing to do just about anything to get better. Unfortunately, the standard of care for cancer is not necessarily the most effective.

Research dating back over a decade suggests many women with breast cancer can opt for gentler versions of chemotherapy, or skip it altogether, without harming their chances of recovery. One 2007 study found some breast cancer patients had better outcomes when given Taxotere, a milder chemotherapy drug than Adriamycin, which had been the standard for decades.1

Another suggested the Oncotype DX test2,3 may be able to help determine whether a breast cancer patient might benefit from chemo by measuring the activity of 21 genes involved in cancer recurrence. At the time, Dr. Eric Winer of the Dana-Farber Cancer Institute in Boston said,4 “We are backing off on chemotherapy and using chemotherapy more selectively.” Now, a number of additional studies have come to the same conclusion: Many breast cancer patients do not need chemotherapy, and have better outcomes without it.

Many Cancer Patients Fare Better Without Chemo

According to the American Society of Clinical Oncology (ASCO), many cancer patients are being overtreated to their detriment; an estimated 70 percent of women with early stage breast cancer probably do not need chemotherapy, and fare just as well without it.5 As reported by NPR:6

“One dramatic example revealed at the [2018 ASCO] meeting relates to the most common form of breast cancer, known as hormone-positive, HER-2 negative disease. For many women who have this diagnosis, but for whom the disease has not spread to lymph nodes, a new study7,8 finds that anti-hormone treatment after surgery is enough, and women won’t benefit from rounds of toxic and uncomfortable chemotherapy.

Treatment of breast cancer for this large group of women will become easier. And for the many women who already choose not to undertake chemotherapy, they can be reassured that it’s the right call. Likewise, researchers from France presented evidence that people with severe colon cancer don’t benefit from a common treatment, which involves heated chemotherapy administered at the time of surgery.

This treatment has been in use for 15 years, without good evidence that it actually works … The study9 of 265 patients found that it didn’t work … The study is ‘an excellent example of how less is more,’ when it comes to certain cancer treatments, says Dr. Andrew Epstein, an oncologist from Memorial Sloan Kettering Cancer Center who spoke on behalf of ASCO.”

Advertisements

With the anomalies noted in Kea deaths, a serious upgrade in monitoring is required for us to see that 1080 is actually doing what DoC says it does

It is very clear we need better accounting of numbers with this poisoning programme.

As this letter by Ron Eddy in yesterday’s Otago Daily Times points out, in 2014 at the start of it’s ‘Battle for the Birds’ programme, the Dept of Conservation claimed there were only 1000 to 2000 Kea left in the wild.

To summarize the info in this letter:

  • DoC recently announce they have “no breed to release programme operating to help increase our declining Kea population”
  • DoC further announces on 28 Oct 2017 that “there are ongoing threats to wild Kea” (Bird of the Year)
  • DoC’s info reveals that “between 2008 and 2014 the government, DoC and Ospri aerial 1080 operations had poisoned 24 out of 199 monitored Kea”
  • We can never know of course how many unmonitored Kea died of 1080 poisoning in the operations (and why aren’t they testing as previously noted with Kiwi deaths to prove that 1080 is actually doing what it purports to?)
  • DoC info supporting the start of the Battle for the Birds programme in 2014 “claimed there were 1,000 to 2,000 Kea left in the wild
  • Even though the department acknowledges that the Kea population is still declining it is now claiming there are 5000 to 7000 Kea left in the wild!

 

1B kea numbers editorial.jpg